Cutler Group’s ProShares UltraPro Short NASDAQ Biotechnology ZBIO Stock Holding History

Cutler Group’s Portfolio ZBIO Stock Details ZBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-1,100	Closed	-$1K	–	5088
2018 Q4	$1K	Buy	+1,100	New	+$20.2K	﹤0.01%	3812
2016 Q4	–	Sell	-200	Closed	-$6K	–	7701
2016 Q3	$6K	Buy	+200	New	+$9.24K	﹤0.01%	4864
2016 Q2	–	Sell	-550	Closed	-$5K	–	7605
2016 Q1	$5K	Sell	550 -500	-48%	-$37K	﹤0.01%	4932
2015 Q4	$18K	Buy	+1,050	New	+$51.7K	﹤0.01%	3538

Other funds holding ZBIO

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cutler Group's ZBIO Position: Q3 2019 in Review

Cutler Group sold out of ProShares UltraPro Short NASDAQ Biotechnology (ZBIO) in Q3 2019, closing a stake of 399 shares — an estimated $5K sold.

Cutler Group first reported a position in ZBIO in Q4 2015 and held it in 11 quarters. The position peaked at $258K in Q4 2015. 5 funds tracked by Wall St. Rank hold ZBIO as of Q3 2019.

Cutler Group reported no remaining ProShares UltraPro Short NASDAQ Biotechnology position as of Q3 2019 after selling out during the quarter.
Cutler Group sold 399 ProShares UltraPro Short NASDAQ Biotechnology shares in Q3 2019, an estimated $5K.
Cutler Group first reported a position in ProShares UltraPro Short NASDAQ Biotechnology in Q4 2015 and held it in 11 quarters.
Cutler Group's ProShares UltraPro Short NASDAQ Biotechnology position peaked at $258K in Q4 2015.
5 funds tracked by Wall St. Rank held ProShares UltraPro Short NASDAQ Biotechnology as of Q3 2019.

Based on Cutler Group's 13F filing for Q3 2019, filed 28 Oct 2019.